FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947778483> ?p ?o ?g. }

• W2947778483 abstract "e12017 Background: Peg is used for CIN prevention. Plin, a novel, non-G-CSF agent is in Phase (Ph) 3 trials for CIN prevention and as an anticancer (NSCLC) agent. In contrast to Peg, Plin does not cause bone pain and maintains absolute neutrophil counts (ANC) within the normal range. Furthermore, Peg, but not Plin, increases Neutrophil-to-Lymphocyte Ratio (NLR) and Lymphocyte-to-Monocyte Ratio (LMR) to immune suppressive values; i.e. NLR>5 and LMR<3.2 (Blayney, ASCO 2018, ESMO 2018, ASCO-SITC 2018). We tested the effects on CIN, bone pain and immune-suppressive profile (i.e. NLR> 5 and LMR<3.2), comparing Plin+half Peg dose to full dose Peg alone (the current CIN standard of care). Methods: Early stage Breast Cancer patients (pts) received high febrile neutropenia (FN) risk TAC (docetaxel, doxorubicin, cyclophosphamide) and either full dose Peg 6 mg (Peg6; n=22) or Peg 3 mg (half dose) + Plin 20 mg/m2 (Peg3/Plin; n = 21) in a Ph 2 trial (NCT03294577). Peg was given ~24 hrs after TAC, and Plin ~30 min after TAC. Blood was drawn for ANC, NLR, MLR daily on Day (D) 0 to D15 in cycle 1. Validated bone pain assessments were done at predose D1, 2,3,4,6,7 and 8 in cycle 1. NLR and LMR were calculated from D6 on (ANC effects with Peg or Plin occur after D6). Results: Grade 4 and Grade 3/4 Neutropenia occurred in 59.1% and 81.2% of pts in the Peg6 arm vs 52.4% and 57.1% in the Peg3/Plin arm. Peg3/Plin was well-tolerated and non-inferior to Peg6 for duration of severe neutropenia (P<0.05). FN occurred in 1 pt each in Peg6 and Peg3/Plin. Bone pain with Peg3/Plin was less vs Peg6: frequency of pts with at least 1,3 or 5 days of bone pain was 90.9%, 36.7% and 18.2 % with Peg6, whereas 33.3%, 14.3% and 4.76% with Peg3/Plin (p<0.0001 for at least 1 day). Frequency of NLR≥5 and LMR≤3.2 was higher with Peg6 vs Peg3/Plin (p<0.045 to P<0.0004 between D8 to D15). Clinical trial information: NCT03294577. Conclusions: Half dose Peg combined with Plin is equally effective against CIN as full dose Peg, but with much less bone pain and immune-suppressive potential.[Table: see text]" @default.
• W2947778483 created "2019-06-07" @default.
• W2947778483 creator A5015687794 @default.
• W2947778483 creator A5032317761 @default.
• W2947778483 creator A5053708169 @default.
• W2947778483 creator A5063300954 @default.
• W2947778483 creator A5069456938 @default.
• W2947778483 creator A5070754234 @default.
• W2947778483 creator A5072667148 @default.
• W2947778483 creator A5080839138 @default.
• W2947778483 creator A5087475785 @default.
• W2947778483 date "2019-05-20" @default.
• W2947778483 modified "2023-10-14" @default.
• W2947778483 title "Plinabulin (Plin) combined with half-dose pegfilgrastim (Peg) compared with full-dose peg alone for chemotherapy- induced-neutropenia (CIN): Neutrophil, bone pain, and immunosuppressive effects." @default.
• W2947778483 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.e12017" @default.
• W2947778483 hasPublicationYear "2019" @default.
• W2947778483 type Work @default.
• W2947778483 sameAs 2947778483 @default.
• W2947778483 citedByCount "0" @default.
• W2947778483 crossrefType "journal-article" @default.
• W2947778483 hasAuthorship W2947778483A5015687794 @default.
• W2947778483 hasAuthorship W2947778483A5032317761 @default.
• W2947778483 hasAuthorship W2947778483A5053708169 @default.
• W2947778483 hasAuthorship W2947778483A5063300954 @default.
• W2947778483 hasAuthorship W2947778483A5069456938 @default.
• W2947778483 hasAuthorship W2947778483A5070754234 @default.
• W2947778483 hasAuthorship W2947778483A5072667148 @default.
• W2947778483 hasAuthorship W2947778483A5080839138 @default.
• W2947778483 hasAuthorship W2947778483A5087475785 @default.
• W2947778483 hasConcept C10138342 @default.
• W2947778483 hasConcept C126322002 @default.
• W2947778483 hasConcept C162324750 @default.
• W2947778483 hasConcept C2776139714 @default.
• W2947778483 hasConcept C2776694085 @default.
• W2947778483 hasConcept C2777063308 @default.
• W2947778483 hasConcept C2778658803 @default.
• W2947778483 hasConcept C2778850193 @default.
• W2947778483 hasConcept C54400483 @default.
• W2947778483 hasConcept C71924100 @default.
• W2947778483 hasConceptScore W2947778483C10138342 @default.
• W2947778483 hasConceptScore W2947778483C126322002 @default.
• W2947778483 hasConceptScore W2947778483C162324750 @default.
• W2947778483 hasConceptScore W2947778483C2776139714 @default.
• W2947778483 hasConceptScore W2947778483C2776694085 @default.
• W2947778483 hasConceptScore W2947778483C2777063308 @default.
• W2947778483 hasConceptScore W2947778483C2778658803 @default.
• W2947778483 hasConceptScore W2947778483C2778850193 @default.
• W2947778483 hasConceptScore W2947778483C54400483 @default.
• W2947778483 hasConceptScore W2947778483C71924100 @default.
• W2947778483 hasLocation W29477784831 @default.
• W2947778483 hasOpenAccess W2947778483 @default.
• W2947778483 hasPrimaryLocation W29477784831 @default.
• W2947778483 hasRelatedWork W180056525 @default.
• W2947778483 hasRelatedWork W2036450045 @default.
• W2947778483 hasRelatedWork W2053128632 @default.
• W2947778483 hasRelatedWork W2258718726 @default.
• W2947778483 hasRelatedWork W2933434293 @default.
• W2947778483 hasRelatedWork W3082112758 @default.
• W2947778483 hasRelatedWork W3135769357 @default.
• W2947778483 hasRelatedWork W3203266297 @default.
• W2947778483 hasRelatedWork W4206195540 @default.
• W2947778483 hasRelatedWork W4289938454 @default.
• W2947778483 isParatext "false" @default.
• W2947778483 isRetracted "false" @default.
• W2947778483 magId "2947778483" @default.
• W2947778483 workType "article" @default.